Akseli Hemminki | Academic Influence

Akseli Hemminki's AcademicInfluence.com Rankings

Akseli Hemminki

Computer Science

#9259

World Rank

#9726

Historical Rank

Machine Learning

#4005

World Rank

#4053

Historical Rank

Artificial Intelligence

#4341

World Rank

#4401

Historical Rank

Database

#6234

World Rank

#6464

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Akseli Hemminki's Degrees

PhD Computer Science University of Helsinki
Masters Computer Science University of Helsinki

Similar Degrees You Can Earn

Why Is Akseli Hemminki Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Akseli Hemminki is a Finnish specialist in Oncology and Radiotherapy, Professor of Oncology and founder of two biotechnology companies. Career Akseli Hemminki worked in University of Alabama at Birmingham in 2000-2002, first as a post doctoral researcher and later as a Research Assistant Professor. Soon after his return to Finland in 2002 he founded his own research group in University of Helsinki, Cancer Gene Therapy Group which he is still leading. In 2007-2013 Hemminki worked as a K. Albin Johansson Research Professor. In 2015 he was appointed as a Jane and Aatos Erkko Professor of Oncology for five years period. Akseli Hemminki has been selected as an "Outstanding Young Person of the World" by Junior Chamber International in 2006.

(See a Problem?)

Akseli Hemminki's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A serine/threonine kinase gene defective in Peutz–Jeghers syndrome (1998) (1673)
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (2003) (1241)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. (2006) (1138)
Consensus guidelines for the detection of immunogenic cell death (2014) (634)
Patterns of metastasis in colon and rectal cancer (2016) (575)
Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis (1997) (522)
Metastatic sites and survival in lung cancer. (2014) (501)
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (2020) (423)
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11, and 14 (2010) (380)
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. (2000) (345)
Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer (1994) (328)
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death (2015) (287)
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. (2002) (284)
Mitochondrial myopathy induces a starvation-like response. (2010) (272)
Metastatic spread in patients with gastric cancer (2016) (242)
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. (2010) (241)
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. (2010) (216)
The molecular basis and clinical aspects of Peutz-Jeghers syndrome (1999) (207)
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. (2002) (200)
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. (2003) (190)
The epidemiology of metastases in neuroendocrine tumors (2016) (185)
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. (2013) (180)
Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity (2011) (173)
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. (2002) (163)
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. (2018) (160)
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus (2013) (157)
Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. (2012) (155)
Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers (2016) (147)
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. (2011) (146)
Modified adenoviruses for cancer gene therapy (2004) (146)
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. (2013) (145)
Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. (2005) (144)
Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA (2008) (142)
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4 (2011) (142)
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. (2007) (141)
Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). (2002) (133)
An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. (2001) (133)
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. (2012) (130)
Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. (2011) (123)
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. (2002) (120)
Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors (2010) (118)
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. (2008) (116)
Survival in cancer of unknown primary site: population-based analysis by site and histology. (2012) (112)
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. (2003) (108)
Tissue-specific promoters for cancer gene therapy (2004) (107)
Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. (2007) (106)
Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. (2003) (105)
Integrin targeted oncolytic adenoviruses Ad5‐D24‐RGD and Ad5‐RGD‐D24‐GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors (2012) (103)
Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer (2005) (98)
An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. (2012) (93)
Oncolytic vaccinia virus for the treatment of cancer (2011) (93)
SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer (2005) (93)
SMAD genes in juvenile polyposis (1999) (93)
Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. (2001) (89)
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. (2007) (89)
Harmful impact of EU clinical trials directive (2006) (88)
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. (2002) (86)
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. (2006) (85)
Multimerization of Adenovirus Serotype 3 Fiber Knob Domains Is Required for Efficient Binding of Virus to Desmoglein 2 and Subsequent Opening of Epithelial Junctions (2011) (85)
Transductional and transcriptional targeting of adenovirus for clinical applications. (2004) (83)
Oncolytic viruses for cancer immunotherapy (2020) (83)
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors (2010) (82)
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. (2009) (79)
Adenoviruses for treatment of cancer (2005) (79)
TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade (2018) (76)
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy (2015) (75)
Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. (2001) (74)
Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy (2016) (72)
An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. (2004) (72)
The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy (2003) (71)
Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. (2012) (70)
Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus (2005) (67)
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. (2009) (67)
Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer (2013) (66)
Oncolytic adenovirus based on serotype 3 (2011) (66)
Population Landscape of Familial Cancer (2015) (64)
Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses (2007) (64)
A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Δ24, for the treatment of advanced breast cancer (2007) (63)
Oncolytic viruses for induction of anti-tumor immunity. (2012) (60)
A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma (2004) (60)
Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor (2015) (58)
Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. (2019) (58)
Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma (2013) (57)
Antiangiogenic Arming of an Oncolytic Vaccinia Virus Enhances Antitumor Efficacy in Renal Cell Cancer Models (2009) (57)
Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. (2008) (56)
Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. (2011) (56)
Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus (2013) (55)
Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus. (2015) (55)
Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. (2001) (55)
Concordant and discordant familial cancer: Familial risks, proportions and population impact (2017) (55)
Infectivity-Enhanced Adenoviruses Deliver Efficacy in Clinical Samples and Orthotopic Models of Disseminated Gastric Cancer (2006) (55)
Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus (2007) (54)
Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter (2009) (53)
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer (2015) (52)
Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. (2009) (52)
Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma (2003) (52)
Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies (2008) (51)
Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1 (2010) (51)
Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. (2012) (51)
Site‐specific survival rates for cancer of unknown primary according to location of metastases (2013) (49)
Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer (2007) (49)
Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer (2004) (49)
Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells (2009) (48)
A New Human DSG2-Transgenic Mouse Model for Studying the Tropism and Pathology of Human Adenoviruses (2012) (48)
Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. (2004) (48)
Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation (2009) (47)
Oncolytic adenovirus and doxorubicin‐based chemotherapy results in synergistic antitumor activity against soft‐tissue sarcoma (2015) (47)
Treatment of prostate cancer with Ad5/3Δ24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo (2007) (45)
A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. (2005) (45)
CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses. (2003) (45)
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy (2015) (44)
Noninvasive imaging for evaluation of the systemic delivery of capsid‐modified adenoviruses in an orthotopic model of advanced lung cancer (2006) (43)
An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. (2001) (43)
Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. (2002) (43)
Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir (2010) (43)
A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses (2009) (42)
Cancer, stem cells, and oncolytic viruses (2008) (42)
Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM‐CSF: Results in vitro, in rodents and in humans (2015) (41)
Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients (2011) (41)
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus (2018) (40)
Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors (2015) (40)
Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans (2014) (40)
Oncolytic adenovirus treatment of a patient with refractory neuroblastoma (2010) (39)
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization (2014) (39)
Inter‐patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy (2004) (39)
Adenoviruses in oncology: a viable option? (2002) (38)
CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging (2013) (38)
Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. (2012) (37)
GMCSF‐armed vaccinia virus induces an antitumor immune response (2015) (36)
Defects in Innate Immunity Render Breast Cancer Initiating Cells Permissive to Oncolytic Adenovirus (2010) (36)
Virotherapy as an approach against cancer stem cells. (2008) (36)
Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries? (2012) (35)
Ad5/3-9HIF-Δ24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment (2009) (35)
Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models (2017) (35)
Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential (2003) (34)
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma. (2016) (34)
Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy. (2018) (33)
Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity (2020) (33)
Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv (2002) (33)
From molecular changes to customised therapy. (2001) (33)
Gene transfer approaches for gynecological diseases. (2006) (32)
Synthesis and biological evaluation of unprecedented ring-expanded nucleosides (RENs) containing the imidazo[4,5-d][1,2,6]oxadiazepine ring system. (2012) (32)
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity (2007) (32)
Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity (2016) (31)
A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy. (2006) (31)
Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. (2010) (30)
Resistance to Two Heterologous Neurotropic Oncolytic Viruses, Semliki Forest Virus and Vaccinia Virus, in Experimental Glioma (2012) (30)
Transcriptional targeting for ovarian cancer gene therapy. (2001) (30)
A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. (2010) (30)
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment (2017) (30)
Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo (2007) (30)
MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver (2013) (30)
Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development (2011) (29)
Time trends in survival from cancer of unknown primary: small steps forward. (2013) (29)
Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia (2019) (29)
Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. (2016) (28)
Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids (2003) (28)
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors (2020) (28)
Oncolytic adenoviruses (2012) (28)
Intestinal cancer in patients with a germline mutation in the down-regulated in adenoma (DRA) gene (1998) (26)
Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer (2016) (26)
Smoking and body mass index as risk factors for subtypes of cancer of unknown primary (2015) (26)
The flt-1 promoter for transcriptional targeting of teratocarcinoma. (2002) (26)
Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer (2016) (26)
Evaluation of tissue‐specific promoters in carcinomas of the cervix uteri (2004) (26)
Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues. (2015) (25)
Systemic Therapy for Cervical Cancer with Potentially Regulatable Oncolytic Adenoviruses (2008) (25)
Power and limits of modern cancer diagnostics: cancer of unknown primary. (2012) (25)
[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer. (2013) (24)
Capsid-modified adenoviral vectors for improved muscle-directed gene therapy. (2012) (24)
Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. (2019) (23)
In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments (2011) (23)
Risk of other Cancers in Families with Melanoma: Novel Familial Links (2017) (23)
Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer (2009) (23)
Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy (2017) (23)
Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. (2016) (23)
Extended release of adenovirus from silica implants in vitro and in vivo (2009) (23)
Site‐specific cancer deaths in cancer of unknown primary diagnosed with lymph node metastasis may reveal hidden primaries (2013) (22)
Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Δ24-hNIS. (2011) (22)
VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22‐HSVTk‐GFP triple fusion construct (2005) (22)
Correction: Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and Plasticity (2011) (22)
A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. (2010) (21)
SPECT/CT Imaging of hNIS -Expression after Intravenous Delivery of an Oncolytic Adenovirus and 131I (2012) (21)
Serotype chimeric and fiber-mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver. (2009) (21)
Optimized Mouse Model for the Imaging of Tumor Metastasis upon Experimental Therapy (2011) (21)
A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients. (2011) (21)
TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling (2020) (20)
Cancer gene therapy with oncolytic adenoviruses. (2009) (20)
Second primary cancers in non‐Hodgkin lymphoma: Bidirectional analyses suggesting role for immune dysfunction (2018) (20)
Serotype Chimeric Human Adenoviruses for Cancer Gene Therapy (2010) (20)
Familial Associations Between Prostate Cancer and Other Cancers. (2017) (20)
Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer. (2012) (20)
T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNF&agr; Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma (2016) (20)
CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy (2018) (20)
Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment (2013) (19)
Gene therapy of gynaecological diseases (2007) (19)
Familial associations of female breast cancer with other cancers (2017) (19)
Molecular imaging and treatment of malignant gliomas following adenoviral transfer of the herpes simplex virus-thymidine kinase gene and the somatostatin receptor subtype 2 gene. (2004) (19)
Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy (2014) (19)
Deficiency of the complex I of the mitochondrial respiratory chain but improved adenylate control over succinate-dependent respiration are human gastric cancer-specific phenomena (2012) (18)
Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery. (2005) (18)
In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders (2014) (18)
Adenoviral production of interleukin‐2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy (2017) (18)
Conditionally replicative adenoviruses for ovarian cancer therapy. (2002) (18)
Syngeneic Syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting (2016) (18)
Oncolytic Immunotherapy: Where Are We Clinically? (2014) (18)
Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles (2015) (17)
Oncolytic Virotherapy Trials—Letter (2013) (16)
Multicellular tumor spheroids in gene therapy and oncolytic virus therapy. (2004) (16)
A three-dimensional assay for measurement of viral-induced oncolysis (2007) (16)
Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System. (2018) (16)
Reaction kinetics of alkyl epoxides with DNA and other nucleophiles. (1994) (15)
Familial Risks and Mortality in Second Primary Cancers in Melanoma (2018) (15)
Location of metastases in cancer of unknown primary are not random and signal familial clustering (2016) (15)
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition (2020) (15)
Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control (2021) (14)
Causes of death in patients with extranodal cancer of unknown primary: searching for the primary site (2014) (14)
Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma. (2006) (14)
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1 (2021) (14)
Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors. (2015) (14)
Effects of capsid‐modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer (2012) (13)
Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden. (2018) (13)
Familial Risks and Proportions Describing Population Landscape of Familial Cancer (2021) (13)
Discovery of a new PCC-mediated stereoselective oxidative spiroketalization process. An access to a new type of poly-THF spiroketal compound displaying anticancer activity (2009) (13)
Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation. (2016) (12)
A century of oncolysis evolves into oncolytic immunotherapy (2016) (12)
Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes (2020) (11)
Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples. (2020) (11)
Common cancers share familial susceptibility: implications for cancer genetics and counselling (2016) (11)
T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses. (2015) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
Discovery of a novel one-step RuO4-catalysed tandem oxidative polycyclization/double spiroketalization process. Access to a new type of polyether bis-spiroketal compound displaying antitumour activity (2010) (11)
Genetics of gallbladder cancer. (2017) (11)
Survival in colon and rectal cancers in Finland and Sweden through 50 years (2021) (10)
Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden (2021) (10)
Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients (2018) (10)
Second primary cancer after female breast cancer: Familial risks and cause of death (2018) (10)
Mutation of the Fiber Shaft Heparan Sulphate Binding Site of a 5/3 Chimeric Adenovirus Reduces Liver Tropism (2013) (10)
Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers (2021) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy (2015) (10)
Second primary cancers in patients with invasive and in situ squamous cell skin carcinoma, Kaposi sarcoma and Merkel cell carcinoma: role for immune mechanisms? (2020) (9)
Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles (2014) (9)
Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients (2019) (9)
Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not (2020) (9)
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1 (2021) (9)
Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition. (2020) (9)
Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy (2018) (8)
Familial associations of male breast cancer with other cancers (2017) (8)
Second primary cancers in non‐Hodgkin lymphoma: Family history and survival (2020) (8)
Treatment of chemotherapy-refractory cancer in the advanced therapy access program. (2012) (8)
Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies. (2016) (8)
Adenoviral E4orf3 and E4orf6 proteins, but not E1B55K, increase killing of cancer cells by radiotherapy in vivo. (2010) (8)
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1 (2022) (8)
Oncolytic Adenoviruses for Cancer Immunotherapy (2012) (7)
A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy (2012) (7)
Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden (2021) (7)
Constitutively active GSK3β as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression (2019) (7)
Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor (2020) (7)
Incidence trends in lung and bladder cancers in the Nordic Countries before and after the smoking epidemic (2021) (7)
Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer (2022) (6)
Multiple myeloma: family history and mortality in second primary cancers (2018) (6)
Radiation-induced upregulation of gene expression from adenoviral vectors mediated by DNA damage repair and regulation. (2012) (6)
Collection and use of family history in oncology clinics. (2014) (6)
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression (2022) (6)
Familial Associations of Colorectal Cancer with Other Cancers (2017) (6)
Familial Associations of Colon and Rectal Cancers With Other Cancers (2019) (5)
Influence of family history on risk of second primary cancers and survival in patients with squamous cell skin cancer (2019) (5)
Adenoviruses in Oncology (2012) (5)
Oncolytic Adenoviruses in the Treatment of Cancer in Humans (2014) (5)
Enhancement of HSV-TK / GCV suicide gene therapy of cancer (2006) (5)
Second Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers (2021) (5)
Incidence Differences Between First Primary Cancers and Second Primary Cancers Following Skin Squamous Cell Carcinoma as Etiological Clues (2020) (5)
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer (2022) (5)
The cyclo‐oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU‐rich 3′‐untranslated region destabilization element can increase specificity (2008) (5)
Produced by a CD 40 L-Encoding Oncolytic Adenovirus Immune Response Is an Important Aspect of the Antitumor Effect (2012) (4)
Oncolytic adenovirus ORCA-010 activates pro-inflammatory myeloid cells and facilitates T cell recruitment and activation by PD-1 blockade in melanoma. (2021) (4)
Calcium Gluconate in Phosphate Buffered Saline Increases Gene Delivery with Adenovirus Type 5 (2010) (4)
The Genetic Basis of Cancer (2005) (4)
Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor (2021) (4)
Long‐term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast (2022) (4)
Incomplete but Infectious Vaccinia Virions Are Produced in the Absence of Oncolysis in Feline SCCF1 Cells (2015) (4)
A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. (2009) (4)
Adenoviruses with an αvβ integrin targeting moiety in the fiber shaft or the HI-loop increase tumor specificity without compromising antitumor efficacy in magnetic resonance imaging of colorectal cancer metastases (2010) (4)
Safety of glucocorticoids in cancer patients treated with oncolytic adenoviruses. (2011) (4)
Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment (2022) (3)
Oncolytic viruses for treatment of cancer (2015) (3)
Long‐term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast? (2022) (3)
Second Primary Cancers After Gastric Cancer, and Gastric Cancer as Second Primary Cancer (2021) (3)
Informing patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example (2020) (3)
Other cancers in lung cancer families are overwhelmingly smoking-related cancers (2017) (3)
Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs. (2019) (3)
Association between tumor characteristics and second primary cancers with cutaneous melanoma survival: A nationwide cohort study (2020) (3)
Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas–Long-Term Follow Up (2021) (3)
Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years (2022) (3)
Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country (2022) (3)
Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers (2022) (3)
Population Landscape of Familial (2015) (2)
Ad5-D24-GMCSF, an oncolytic adenovirus coding for GMCSF, induces anti-tumoral immunity in human cancer patients (2009) (2)
Oncolytic adenovirus research and applications (2010) (2)
Novel cGMP liposomal vectors mediate efficient gene transfer (2003) (2)
Abstract B16: Enabling checkpoint inhibitors with oncolytic viruses to deliver complete responses: A matter of timing (2020) (2)
Cancer Predisposition Genes in Cancer-Free Families (2020) (2)
Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers (2022) (2)
Second Primary Cancers in Melanoma Patients Critically Shorten Survival (2020) (2)
Survival in Colon, Rectal and Small Intestinal Cancers in the Nordic Countries through a Half Century (2023) (2)
An evaluation of local and systemic immune markers following intratumoral administration of a chimeric adenovirus Ad5/3-D24-GMCSF in refractory cancer patients with solid tumors. (2015) (2)
Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries (2022) (2)
Gene expression analysis of tumors demonstrates an induction of Th1 type immune response following intratumoral administration of ONCOS-102 in refractory solid tumor patients (2014) (2)
648. Transductionally Modified Oncolytic Adenoviruses for Treatment of Advanced Pancreatic Cancer (2006) (2)
Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis. (2014) (2)
The challenges of understanding cancer of unknown primary (2013) (2)
Oncolytic Adenovirus Expressing Cytokines Enhances Anti-Tumor Efficacy of Mesothelin-Redirected CAR-T Cells (2016) (2)
Replication-competent viruses for cancer therapy (2004) (2)
515. Oncolytic Adenovirus Armed with Cytokines Enhances CAR-T Cell Efficacy in Pancreatic Tumor Model (2016) (2)
1032TiP A phase I, first-in-human, study of TILT-123, a tumor-selective oncolytic adenovirus encoding TNFa and IL-2, in participants with advanced melanoma receiving adoptive T-cell therapy with tumor-infiltrating lymphocytes (2021) (2)
Treatment of cancer patients with capsid modified double controlled oncolytic adenovirus Ad5/3-Cox2L-D24 (2008) (1)
Causes of death in patients with extranodal cancer of unknown primary: searching for the primary site (2014) (1)
71. Boosting the Immunogenicity of an Oncolytic Vaccinia Virus By Expression of DAI Can Enhance Anti-Tumor Immunity in Humanized Mice (2015) (1)
Portrait of a Leader in Immunotherapeutics (2012) (1)
Survival in gastric and esophageal cancers in the Nordic countries through a half century. (2023) (1)
51PDelivering complete responses against solid tumors by checkpoint blockade enabled with tumor necrosis factor alpha and interleukin-2 armed adenoviruses (2017) (1)
80P Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples (2020) (1)
Safety and efficacy of Ad5/3-D24-GMCSF, a serotype 5/3 chimeric oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor (GM-CSF), in treatment of metastatic and refractory solid tumors. (2010) (1)
[Adenoviruses in cancer therapy]. (2005) (1)
102P TNFa and IL-2 armed adenovirus promotes abscopal effect in mice treated with anti-PD-1 immunotherapy (2020) (1)
Advances in Brief CD 40 Is Expressed on Ovarian Cancer Cells and Can Be Utilized for Targeting Adenoviruses 1 (2003) (1)
INHERITED PREDISPOSITION TO GASTROINTESTINAL CANCER : THE MOLECULAR BACKGROUNDS OF PEUTZ-JEGHERS SYNDROME AND HEREDITARY NON-POLYPOSIS COLORECTAL CANC ER (1999) (1)
The epithelial architecture of ovarian cancer cells mediates resistance to oncolytic adenoviruses (2009) (1)
Advances in Brief Treatment of Ovarian Cancer with a Tropism Modified Oncolytic Adenovirus 1 (2002) (1)
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting (2023) (1)
Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer (2013) (1)
35PCombination immunotherapy with oncolytic adenovirus and adoptive T-cell transfer leads to systemic anti-tumor immunity and enhanced therapeutic efficacy in a preclinical melanoma model (2015) (1)
Oncolytic adenovirus improves anti-tumor efficacy of adoptive T cell therapy by breaking tumor-induced immunosuppression and peripheral tolerance (2015) (1)
328. An Orthotopic Murine Model of Advanced Breast Cancer for Imaging and Comparison of Targeting Moieties (2005) (1)
Modified Adenoviruses for Gene Therapy (2003) (1)
136 Tumor-infiltrating lymphocytes (TILs) following intratumoral administration of ONCOS-102 are associated with prolonged overall survival in last line solid tumor patients (2014) (1)
Types of second primary cancer influence overall survival in cutaneous melanoma (2021) (1)
Crossing the valley of death with advanced cancer therapy (2015) (1)
TILT Biotherapeutics (2017) (1)
SPECT / CT Imaging of hNIS-Expression after Intravenous Delivery of an Oncolytic Adenovirus and I-131 Rajecki (1)
672. Adoptive Therapy Evaluating Human IL13-Zetakine T Cells Engineered To Target Glioblastomas Expressing IL13RÎ±2, a Biomarker Predicting Poor Prognosis (2016) (1)
EVALUATION OF FIVE CONDITIONALLY REPLICATIVE ADENOVIRUSES FOR OVARIAN CANCER THERAPY (2004) (1)
Corrigendum to "Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma". (2016) (1)
1109 POSTER Personalized Cancer Immunotherapy With Oncolytic Adenoviruses Armed With Immunostimulatory Molecules GMCSF or CD40L (2011) (0)
Enabling successful T-cell therapy of solid tumors with oncolytic adenoviruses armed with TNFα and IL-2 (2016) (0)
Erratum: Power and limits of modern cancer diagnostics: Cancer of unknown primary [Ann Oncol, 23, (2012), (760-764)] doi:10.1093/annonc/mdr369 (2017) (0)
Oncolytic adenoviruses and certain chemotherapeutics can induce autophagy and immunogenic cancer cell death (2013) (0)
895: Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse model (2014) (0)
296. TLR9 Signaling and Regulatory T-Cells Orchestrate the Immune Response to the Transgene Product in Muscle (2016) (0)
Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment (2013) (0)
1004. Enhanced Survival Uncovers Liver Toxicity in Mice with Orthotopic Advanced Ovarian Cancer Treated with Gemcitabine and Ad5/3-|[Delta]|24, a Serotype 3 Receptor Targeted Oncolytic Adenovirus (2005) (0)
7PDOncolytic immunotherapy for enabling dendritic cell therapy (2016) (0)
Author reply (0)
418. Peripheral Blood Leucocytes, Neutralizing Antibodies and Tumor Burden as Predictive and Prognostic Factors in Patients Treated with Oncolytic Adenoviral Immunotherapy (2016) (0)
Autoimmune diseases as comorbidities for liver, gallbladder, and biliary duct cancers in Sweden (2023) (0)
Familial Associations of Colorectal Cancer with Other Cancers (2017) (0)
Oncolytic adenovirus for treatment of malignant ascites (2022) (0)
Interleukin-8 (IL-8), prognostic and predictive biomarkers and compositions, and vectors for use in immunotherapy oncolytic (2016) (0)
970. A Fiber Modified SLPI Promoter Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer (2004) (0)
1026. In Vivo Imaging for Evaluation of Adenoviral Capsid Modifications for Systemic Delivery in an Orthotopic Model of Locally Advanced Lung Cancer (2005) (0)
[Tumour-dependent replicating adenoviruses in the treatment of carcinomas]. (2004) (0)
Informing patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example (2020) (0)
INTERNATIONAL SYMPOSIUM ON RADIOPHARMACEUTICAL THERAPY HELSINKI, 18-20 NOVEMBER 2018 (2019) (0)
52P MUC1 targeted immunotherapy with an oncolytic adenovirus coding for a bispecific T cell engager (2022) (0)
Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment (2022) (0)
Long‐term survival trends in solid cancers in the Nordic countries marking timing of improvements (2022) (0)
Translational Cancer Research : Gene Therapy by Viral and Non-viral Vectors (2014) (0)
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials (2022) (0)
Synthesis and Biological Evaluation of Unprecedented Ring‐Expanded Nucleosides (RENs) Containing the Imidazo[4,5‐d][1,2,6]oxaidazepine Ring System. (2013) (0)
Ad-199T therapeutic activity against DENA-induced tumors in HCC mouse model. (2013) (0)
Abstract B80: Patients treated with oncolytic adenovirus Ad5/3-hTERT-E2F-Δ24-GMCSF induce immunological antitumor responses (2015) (0)
Abstract A30: Molecular insight into pathogen-associated molecular pattern signaling during TNFa and IL2 armed oncolytic adenovirus treatments (2020) (0)
CD40L coding oncolytic adenovirus 3 is a potent facilitator of dendritic cell therapy. (2017) (0)
50P Enhancing TIL and NK cells adoptive therapies with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer (2022) (0)
4019 POSTER Phase III, randomized, open-label study of triweekly docetaxel (tT) vs. biweekly docetaxel (bT) as treatment for advanced hormone refractory prostate cancer (HRPC): findings from an interim safety analysis (2007) (0)
Cox-2 driven infectivity enhanced CRAds for cancer treatment (2005) (0)
CGTG-102 (Ad5/3-D24-GMCSF), a novel oncolytic adenovirus, in patients with refractory solid tumors: Experience from an advanced therapy access program. (2012) (0)
Immune response is an important aspect of the anti-tumor effect produced by a CD40L- encoding oncolytic adenovirus Running title: Oncolytic adenovirus coding for CD40L Authors and affiliations (2012) (0)
410. Oncolytic Adenoviruses Armed with TNFa and IL-2 Induce Antitumor Immune Responses and Protection from Tumor Rechallenge (2016) (0)
66PReplacing lymphodepleting preconditioning with an oncolytic adenovirus coding for tumor necrosis factor alpha and interleukin-2 in adoptive cell therapy (2017) (0)
Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2 (2015) (0)
Abstract B063: Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive T cell therapy of solid tumors (2016) (0)
Revamping the ovarian tumour microenvironment with an oncolytic adenovirus yields enhanced tumour-infiltrating lymphocyte anti-tumour activity (2019) (0)
Influence of family history on risk of second primary cancers and survival in squamous cell skin cancer patients (2019) (0)
2PDOncolytic adenoviruses armed with TNFα and IL-2 enable successful adoptive T-cell therapy of solid tumors (2015) (0)
438. Oncolytic Immunotherapy for Treatment of Breast Cancer, Including Triple-Negative Breast Cancer (2015) (0)
646. Utilization of Human Mesenchymal Stem Cells for Delivery of Targeted Oncolytic Adenoviruses into Orthotopic Lung Tumors (2006) (0)
Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival (2015) (0)
Enhancing the therapeutic effect of dendritic cell therapy by oncolytic adenovirus 3 encoding CD40-ligand (2019) (0)
In vivo magnetic resonance imaging (MRI) and spectroscopy (MRS) identifies oncolytic adenovirus responders. (2014) (0)
1010. A |[beta]|-hCG Expressing Trackable and Tumor Targeted Conditionally Replicating Adenovirus for Treatment of Prostate Cancer (2005) (0)
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors (2022) (0)
299. In Vivo Luciferase Imaging for Analysis of Oncolytic Adenoviruses for Renal Cell Cancer (2006) (0)
Power and limits of modern cancer diagnostics: cancer of unknown primary. (2017) (0)
652. Culture and Characterization of Tumor-Infiltrating Lymphocytes of the Syrian Hamster (2016) (0)
CLEP_A_230149 105..112 (2020) (0)
REVIEW Transcriptional Targeting for Ovarian Cancer Gene Therapy (2001) (0)
Thank you to our reviewers (2023) (0)
Systemic Strategies for Tumor Targeting (2003) (0)
[18F]-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Response Evaluation of Oncolytic Adenovirus Treatments of Patients with Advanced Cancer - Supplemental Material (2013) (0)
405. IL-2 and TNF-a Coding Adenoviruses Enable Adoptive T Cell Therapy in Metastatic, Solid Cancer by Systemically Activating Tumor-Reactive TILs (2016) (0)
Preclinical studies of oncolytic adenovirus 3 coding for CD40L as an enabler of dendritic cell therapy. (2017) (0)
54PT-cell therapy: Enabling oncolytic adenoviruses for the treatment of melanoma (2017) (0)
Abstract A15: Rewiring the tumor microenvironment with an oncolytic virus to enhance and support tumor-infiltrating lymphocytes for ovarian cancer immunotherapy (2020) (0)
Survival in melanoma in the nordic countries into the era of targeted and immunological therapies. (2023) (0)
Multiple myeloma: family history and mortality in second primary cancers (2018) (0)
Analysis of predictive and prognostic factors in 290 patients treated with oncolytic adenoviruses (2015) (0)
Abstract B18: Adoptive T-cell transfer combined with murine cytokine-armed adenoviruses for the treatment of melanoma (2015) (0)
442. Novel cox-2 Driven Infectivity Enhanced CRAds for Treatment of Ovarian Cancer (2004) (0)
Dasatinib-Induced Reduction of Tumor Growth Is Accompanied By the Changes in the Immune Profile in a Melanoma B16.OVA Mouse Model (2014) (0)
Phase III, randomized, open-label study of triweekly docetaxel versus biweekly docetaxel as treatments for advanced hormone-refractory prostate cancer: Findings from an interim safety analysis of the Finnish Uro-oncological Group Study 1-2003. (2011) (0)
647. Evaluation of Dose, Scheduling, Combination with Chemotherapy and Specificity of Ad5/3 Fiber-Chimeric Oncolytic Adenoviruses for Treatment of Ovarian Cancer (2006) (0)
Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor (2021) (0)
Oncolytic adenoviral vectors, and methods and uses relating thereto (2009) (0)
Abstract B07: Oncolytic adenovirus 3 coding for CD40L as an enhancer of dendritic cell therapy (2020) (0)
Adenoviruses armed with TNFa and IL-2 increase efficacy of adoptive cell therapy even in the absence of preparative lymphodepleting conditioning (2017) (0)
Abstract B21: Combination of adenovirus and adoptive T-cell therapy breaks tumor tolerance by recruiting immune cells to and promoting their activity in the tumor (2015) (0)
299. Increasing Gene Transfer and Oncolytic Potency of Adenoviruses in Orthotopic Models of Gastric Cancer (2005) (0)
Abstract A08: Adenovirus coding for TNF-α and IL-2 proteins mediates abscopal effect in mice receiving anti-PD1 immunotherapy (2020) (0)
Delivering complete responses against solid tumors by checkpoint blockade enabled with TNFa and IL-2 armed adenoviruses (2017) (0)
Survival in Lung Cancer in the Nordic Countries Through A Half Century (2023) (0)
Adenoviruses with an a v b integrin targeting moiety in the fiber shaft or the HI-loop increase tumor specificity without compromising antitumor efficacy in magnetic resonance imaging of colorectal cancer metastases (2010) (0)
Experimental Glioma Forest Virus and Vaccinia Virus, in Neurotropic Oncolytic Viruses, Semliki Resistance to Two Heterologous (2014) (0)
Abstract 3643: Tumor-specific oncolytic adenovirus coding for trastuzumab results in local production of functional monoclonal antibody from tumor cells (2014) (0)
RGD Modification In The HI Loop Of The Fiber Knob Diminishes Immunogenicity Of Type 5 Adenoviral Vectors (2003) (0)
Increasing Responses to T-Cell Therapies in Solid Tumours by the Use of an Engineered Adenovirus Coding for TNFa and IL-2 (2019) (0)
960. Regulation of Cyclooxygenase-2 and Vascular Endothelial Growth Factor Promoter Based Conditionally Replicating Adenoviruses for Treatment of Cervical Cancer (2004) (0)
Causes of death in patients with extranodal cancer of unknown primary (0)
194. Adenoviruses Armed with TNFα and IL-2 Successfully Enable Adoptive T-Cell Therapy (2016) (0)
950. |[beta]|hCG Expressing CRAd for Prostate Cancer (2006) (0)
Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients (2019) (0)
Abstract B07: Characterization of T-cell therapy enhancing oncolytic adenoviruses with human cytokine expression (2015) (0)
723. Oncolytic Adenovirus Breaks Tumor Tolerance To Adoptive T-Cell Therapy By Recruiting Immune Cells To and Promoting Their Activity in the Tumor (2015) (0)
1028. Reduction of Replication of Oncolytic Adenoviruses with Pharmacological Intervention: Treatment of Replication Associated Toxicity (2005) (0)
1. Translational Cancer Research (2014) (0)
Abstract B51: Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans (2015) (0)
Deficiency of the complex I of the mitochondrial respiratory chain but improved adenylate control over succinate-dependent respiration are human gastric cancer-specific phenomena (2012) (0)
Author’s response to reviews Title: INFORMING PATIENTS ABOUT THEIR MUTATION TESTS: CDKN2A c.256G>A IN MELANOMA AS AN EXAMPLE Authors: (2020) (0)
Corrigendum to "Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma". (2016) (0)
Abstract 3304: Oncolytic adenovirus with low-dose temozolomide induces autophagy and antitumor immune responses preclinically and in cancer patients. (2013) (0)
lymphoma cells to rituximab therapy A recombinant adenovirus type 35 fiber knob protein sensitizes (2010) (0)
Immunologic Responses in Patients CD 40 L-Expressing Replicating Adenovirus : Assessment of Safety Oncolytic Immunotherapy of Advanced Solid Tumors with a Updated (2012) (0)
Advances in Brief Targeting Oncolytic Adenoviral Agents to the Epidermal Growth Factor Pathway with a Secretory Fusion Molecule 1 (2001) (0)
Enabling Immune checkpoint blockade with oncolytic viruses armed with TNFa and IL-2. (2017) (0)
Adenovirus vectors and methods and uses related (2010) (0)
ADENOVIRAL E 4 ORF 3 AND E 4 ORF 6 PROTEINS , BUT NOT E 1 B 55 K , INCREASE KILLING OF CANCER CELLS BY RADIOTHERAPY IN VIVO (2010) (0)
51P Immunological analysis of blood from patients with solid tumors treated with TILT-123: An oncolytic adenovirus encoding for tumor necrosis factor alpha (TNFa) and interleukin 2 (IL-2) (2022) (0)
Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs (2022) (0)
Guse Capsid-modified adenoviral vectors for muscle-directed gene therapy Hum Gene Ther 2012 (2013) (0)
Abstract 2587: Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse model (2014) (0)
Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus Callegari , Elisa 2013-09-12 (0)
The effects of a TNFa and IL2 armed oncolytic adenovirus on pathogen associated molecular pattern signaling. (2017) (0)

This paper list is powered by the following services:

Other Resources About Akseli Hemminki

en.wikipedia.org

What Schools Are Affiliated With Akseli Hemminki?

Akseli Hemminki is affiliated with the following schools: